ERBB2 and gastric cancer: There are significant efforts to improve treatment for advanced and metastatic GC which can be divided into two main directions: improvement of drugs or antibodies against known targets such as HER2, PD-1, or VEGF, and development of agents against novel targets, notably FGFR2b.